PLX Protalix BioTherapeutics, Inc.

0.91
+0.00  (0%)
Previous Close 0.91
Open 0.97
Price To book 0.00
Market Cap 115.11M
Shares 126,499,000
Volume 1,156,667
Short Ratio 2.03
Av. Daily Volume 2,643,930

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 17830242
  2. 8-K - Current report 17828497
  3. 8-K - Current report 17824447
  4. 8-K - Current report 17766001
  5. 8-K - Current report 17758054

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to commence 3Q 2017.
Pegunigalsidase alfa (PRX-102)
Fabry Disease
Approved May 1, 2012.
Taliglucerase alfa
Gaucher disease
Phase 3 dosing commenced October 2016. Enrollment to be completed 2H 2017 with data in 2018.
PRX-102
Fabry disease
Phase 2 interim data released January 3, 2017. Full data released April 12, 2017. Company noted data were positive but results showed efficacy down on January data.
AIR DNase (PRX-110)
Cystic Fibrosis
Phase 2 trial initiation announced November 30, 2016. Data due around the end of 2017.
OPRX-106
Ulcerative Colitis

Latest News

  1. Protalix BioTherapeutics to Present at the Jefferies 2017 Global Healthcare Conference
  2. Protalix BioTherapeutics Announces Presentation of Phase II Clinical Trial Results for alidornase alfa in Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference
  3. Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
  4. Edited Transcript of PLX earnings conference call or presentation 10-May-17 12:30pm GMT
  5. Protalix reports 1Q loss
  6. Protalix BioTherapeutics Reports 2017 First Quarter Results and Provides Corporate Update
  7. Protalix Announces FDA Investigational New Drug Clearance to Commence Once-Monthly Dosing Study of pegunigalsidase alfa (PRX-102) for the Treatment of Fabry Disease
  8. Protalix BioTherapeutics to Hold First Quarter 2017 Financial Results and Corporate Update Conference Call on May 10, 2017
  9. Protalix BioTherapeutics Announces New Preclinical Results Demonstrating a Positive Effect of pegunigalsidase alfa (PRX-102) on Small-fiber Neuropathy in Fabry Disease Models Compared to Commercially Available Enzyme Replacement Therapies
  10. Apricus Biosciences and Protalix Biotherapeutics Seeing Opposite Sides of FDA Clinical Trials
  11. Protalix Cystic Fibrosis Drug Study Results Worsen Over Time
  12. Protalix BioTherapeutics Announces Positive Results from Phase II Clinical Trial of alidornase alfa (AIR DNase™) for the Treatment of Cystic Fibrosis
  13. Do Options Traders Know Something About Protalix (PLX) Stock We Don't?
  14. Blog Coverage Kitov Received a $2 Million Filing Waiver from FDA
  15. Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  16. Protalix BioTherapeutics Reports 2016 Full Year Results and Provides Corporate Update
  17. Cerulean Pharma Attracts Investors and Possible Suitor, Protalix Returns to the Spotlight
  18. Today's Research Report on Trending Biotech Tickers: Protalix Biotherapeutics and Stemline Therapeutics
  19. Protalix BioTherapeutics to Hold Full-Year 2016 Financial Results and Corporate Update Conference Call on March 16, 2017
  20. Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 17830242
  2. 8-K - Current report 17828497
  3. 8-K - Current report 17824447
  4. 8-K - Current report 17766001
  5. 8-K - Current report 17758054
  6. 8-K - Current report 17757010
  7. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17722309
  8. DEF 14A - Other definitive proxy statements 17694833
  9. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 17694548
  10. 8-K - Current report 17692927